Issue Demand outruns the care pathway, pushing patients into channels of their own

Summary

An executive at Novo Nordisk tells PwC that obesity care still offers few clear routes to a GLP-1 prescription, so patients locate access through new channels themselves - a mismatch between consumer-led demand and an institution-shaped supply route.